Barrington lowered the firm's price target on Concentrix to $38 from $62 and keeps an Outperform rating on the shares. following the fiscal Q1 report. The firm believes the company gained market share and wallet share in the quarter. The analyst cites increased execution risk given the "slippage" reported in the quarter for the target cut.
